Product Information
EXFORGE HCT 10-320-25 MG TAB is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $15.4477 per EA under NDC 00078056315. Its NADAC has been published 555 times since Nov 28, 2013.
FDA first approved this application on Apr 30, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 25; 320 mg/1; mg/1; mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078056315
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/7/2026
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTANApproval Type
New Drug (NDA)
FDA Application
NDA022314FDA Approved
4/30/2009
TE Code
AB
On Market Since
4/4/2009
Pharmacological Classes
Price Statistics
The NADAC for EXFORGE HCT 10-320-25 MG TAB has been published 555 times since Nov 28, 2013, and over the history we have for it it has risen 147.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.4477 per EA |
|---|---|
| All-time high | $15.4477 (Sep 30, 2026) |
| All-time low | $6.2477 (Nov 28, 2013) |
| 52-week high | $15.4477 |
| 52-week low | $14.9978 |
| Median price | $12.3161 |
| Average price | $11.7944 |
| Largest weekly change | +19.5% (Apr 15, 2015) |
| Weeks tracked | 555 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the amlodipine valsartan and hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novartis Pharmaceuticals Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
amlodipine valsartan and hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EXFORGE HCT 10-320-25 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for EXFORGE HCT 10-320-25 MG TAB, manufactured by Novartis Pharmaceuticals Corporation, is $15.4477 per EA (NDC 00078056315), effective Sep 30, 2026.
How has the price of EXFORGE HCT 10-320-25 MG TAB changed over time?
Over the history we have for it, the NADAC for EXFORGE HCT 10-320-25 MG TAB has risen 147.3%. It has been tracked across 555 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EXFORGE HCT 10-320-25 MG TAB?
Since Nov 28, 2013, the NADAC for EXFORGE HCT 10-320-25 MG TAB has ranged from a low of $6.2477 (Nov 28, 2013) to a high of $15.4477 (Sep 30, 2026), with a median of $12.3161 per EA.
Are there cheaper alternatives to EXFORGE HCT 10-320-25 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of EXFORGE HCT 10-320-25 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EXFORGE HCT 10-320-25 MG TAB?
EXFORGE HCT 10-320-25 MG TAB (NDC 00078056315) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.